SynAgile Corporation announces the closing of the financing,


WILSON, Wyoming, September 22, 2021 (GLOBE NEWSWIRE) – SynAgile Corporation (www.SynAgile.com), a private pharmaceutical company that develops and markets drug delivery systems using its proprietary OraFuse® technology platform, today announced the closing of a convertible debt investment of more than $ 9 million. Proceeds from the sale will be used to complete the Phase 2 clinical trial of DopaFuse® delivery system and initiate full-scale manufacturing for its Phase III trial. The Phase II trial is currently underway in Luxembourg, Italy and Spain. The DopaFuse delivery system is the first non-invasive and continuous delivery system for levodopa-carbidopa. DopaFuse has the potential to treat motor fluctuations and dyskinesias associated with Parkinson’s disease.

Along with the funding, Mr. Michael McNamara joined the SynAgile Board of Directors. Mr. McNamara spent 12 years as CEO of Flex, one of the world’s largest multinational technology manufacturing companies, where he grew the company to $ 25 billion in revenue and over 200,000 employees operating in more than 30 countries. Mr. McNamara sits on the boards of Carrier, Workday and PCH International, and has served on the boards of many other companies, including Slack Technologies, Delphi, SunEdison and Therasense. He is also a venture capital partner at Eclipse Ventures.

SynAgile also announces the appointment of Dr. C. Warren Olanow as Medical Director of SynAgile. Dr Olanow has been an advisor to SynAgile since 2011. He is the past chair of the Department of Neurology at the Mount Sinai School of Medicine in New York. Dr. Olanow is the co-founder and CEO of Clintrex, a clinical research company. Dr. Olanow’s research has focused on the cause and treatment of PD and other neurodegenerative diseases. He has led several pivotal clinical trials leading to the approval of numerous drugs and is the recipient of the 2013 American Academy of Neurology Movement Disorders Research Award and Lifetime Achievement Award from the International Parkinson and Movement Disorder Society.

About SynAgile

SynAgile is a pharmaceutical company focused on the development and commercialization of therapeutic products using its proprietary OraFuse® non-invasive continuous oral dosing technology, with an initial focus on treating debilitating motor complications in Parkinson’s disease patients using its DopaFuse® levodopa-carbidopa delivery system.

SOURCE SynAgile Corporation


About Larry Noble

Check Also

KPRA Reports Successfully Running “Restaurant Bill Monitoring System” – Business & Finance

PESHAWAR: The Khyber Pakhtunkhwa Revenue Authority (KPRA) is successfully operating the Restaurant Invoice Monitoring System …

Leave a Reply

Your email address will not be published.